SELLAS Life Sciences Group (SLS) Stock Forecast, Price Target & Predictions
SLS Stock Forecast
SELLAS Life Sciences Group stock forecast is as follows: an average price target of $7.00 (represents a 488.24% upside from SLS’s last price of $1.19) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
SLS Price Target
The average price target for SELLAS Life Sciences Group (SLS) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $6.00. This represents a potential 488.24% upside from SLS's last price of $1.19.
SLS Analyst Ratings
According to 2 Wall Street analysts, SELLAS Life Sciences Group's rating consensus is 'Buy'. The analyst rating breakdown for SLS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
SELLAS Life Sciences Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2022 | - | Industrial Alliance Securities | $8.00 | $2.23 | 258.74% | 572.27% |
| Jun 28, 2022 | - | Cantor Fitzgerald | $6.00 | $2.32 | 158.62% | 404.20% |
The latest SELLAS Life Sciences Group stock forecast, released on Nov 15, 2022 by Industrial Alliance Securities company, set a price target of $8.00, which represents a 258.74% increase from the stock price at the time of the forecast ($2.23), and a 572.27% increase from SLS last price ($1.19).
SELLAS Life Sciences Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.19 | $1.19 | $1.19 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of SELLAS Life Sciences Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SELLAS Life Sciences Group's last price of $1.19. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2022 | Alliance Global Partners | Buy | Buy | Hold |
| Jun 28, 2022 | Cantor Fitzgerald | Overweight | Overweight | Hold |
SELLAS Life Sciences Group's last stock rating was published by Alliance Global Partners on Nov 15, 2022. The company gave SLS a "Buy" rating, the same as its previous rate.
SELLAS Life Sciences Group Financial Forecast
SELLAS Life Sciences Group Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Mar 21 | Mar 15 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $5.70M | $2.75M | $2.17M |
| Avg Forecast | - | - | - | - | - | - | - | $13.00M | $13.00M | $7.22M | $2.97M | $7.46M |
| High Forecast | - | - | - | - | - | - | - | $13.00M | $13.00M | $8.66M | $3.57M | $8.95M |
| Low Forecast | - | - | - | - | - | - | - | $13.00M | $13.00M | $5.78M | $2.38M | $5.97M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 12 | 15 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.79% | 0.92% | 0.29% |
SELLAS Life Sciences Group's average Quarter revenue forecast for Sep 23 based on 1 analysts is $13.00M, with a low forecast of $13.00M, and a high forecast of $13.00M. SLS's average Quarter revenue forecast represents a 128.07% increase compared to the company's last Quarter revenue of $5.70M (Mar 21).
SELLAS Life Sciences Group EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Mar 21 | Mar 15 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 12 | 15 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $94.00K | $-2.40M | $-10.03M | $-1.99M |
| Avg Forecast | - | - | - | - | - | - | - | $-2.60M | $-2.60M | $-3.04M | $-10.78M | $-3.06M |
| High Forecast | - | - | - | - | - | - | - | $-2.60M | $-2.60M | $-2.44M | $-8.63M | $-2.45M |
| Low Forecast | - | - | - | - | - | - | - | $-2.60M | $-2.60M | $-3.65M | $-12.94M | $-3.67M |
| Surprise % | - | - | - | - | - | - | - | - | -0.04% | 0.79% | 0.93% | 0.65% |
3 analysts predict SLS's average Quarter EBITDA for Dec 23 to be $-2.60M, with a high of $-2.60M and a low of $-2.60M. This is -2865.96% lower than SELLAS Life Sciences Group's previous annual EBITDA (Sep 23) of $94.00K.
SELLAS Life Sciences Group Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Mar 21 | Mar 15 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 12 | 15 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $-9.27M | $-2.40M | $-10.54M | $-2.54M |
| Avg Forecast | $-6.34M | $-6.34M | $-6.34M | $-6.92M | $-6.72M | $-7.30M | $-9.99M | $4.99M | $1.01M | $-3.04M | $-11.33M | $-3.90M |
| High Forecast | $-6.34M | $-6.34M | $-6.34M | $-6.92M | $-6.72M | $-6.18M | $-9.99M | $4.99M | $1.01M | $-2.44M | $-9.06M | $-3.12M |
| Low Forecast | $-6.34M | $-6.34M | $-6.34M | $-6.92M | $-6.72M | $-8.42M | $-9.99M | $4.99M | $1.01M | $-3.65M | $-13.59M | $-4.68M |
| Surprise % | - | - | - | - | - | - | - | - | -9.19% | 0.79% | 0.93% | 0.65% |
SELLAS Life Sciences Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
SELLAS Life Sciences Group SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Mar 21 | Mar 15 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 12 | 15 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $3.55M | $3.56M | $7.57M | $6.92M |
| Avg Forecast | - | - | - | - | - | - | - | $54.92M | $54.92M | $4.51M | $12.56M | $31.51M |
| High Forecast | - | - | - | - | - | - | - | $54.92M | $54.92M | $5.41M | $15.07M | $37.82M |
| Low Forecast | - | - | - | - | - | - | - | $54.92M | $54.92M | $3.61M | $10.05M | $25.21M |
| Surprise % | - | - | - | - | - | - | - | - | 0.06% | 0.79% | 0.60% | 0.22% |
SELLAS Life Sciences Group's average Quarter SG&A projection for Dec 23 is $54.92M, based on 3 Wall Street analysts, with a range of $54.92M to $54.92M. The forecast indicates a 1447.99% rise compared to SLS last annual SG&A of $3.55M (Sep 23).
SELLAS Life Sciences Group EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Mar 21 | Mar 15 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 12 | 15 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.16 | $-2.40K | $-600.01 |
| Avg Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.12 | $-0.12 | $-0.13 | $-0.17 | $0.09 | $0.02 | $-0.18 | $-1.86 | $-3.17K |
| High Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.12 | $-0.12 | $-0.11 | $-0.17 | $0.09 | $0.02 | $-0.18 | $-1.49 | $-2.54K |
| Low Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.12 | $-0.12 | $-0.15 | $-0.17 | $0.09 | $0.02 | $-0.18 | $-2.23 | $-3.81K |
| Surprise % | - | - | - | - | - | - | - | - | -0.02% | 0.89% | 1290.34% | 0.19% |
According to undefined Wall Street analysts, SELLAS Life Sciences Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLS previous annual EPS of $NaN (undefined).
SELLAS Life Sciences Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.04 | $5.50 | 13650.00% | Buy |
| NLSP | NLS Pharmaceutics | $0.13 | $6.00 | 4515.38% | Buy |
| ELEV | Elevation Oncology | $0.63 | $9.00 | 1328.57% | Buy |
| KOD | Kodiak Sciences | $2.31 | $32.80 | 1319.91% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.35 | $10.00 | 640.74% | Buy |
| SLS | SELLAS Life Sciences Group | $1.19 | $7.00 | 488.24% | Buy |
| EYPT | EyePoint Pharmaceuticals | $7.97 | $30.00 | 276.41% | Buy |
| IMMX | Immix Biopharma | $1.97 | $7.00 | 255.33% | Buy |
| ANVS | Annovis Bio | $7.87 | $23.50 | 198.60% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| ZURA | Zura Bio | $3.62 | $5.00 | 38.12% | Buy |
| MCRB | Seres Therapeutics | $0.95 | $1.25 | 31.58% | Buy |
| AXSM | Axsome Therapeutics | $93.19 | $118.08 | 26.71% | Buy |
SLS Forecast FAQ
Is SELLAS Life Sciences Group a good buy?
Yes, according to 2 Wall Street analysts, SELLAS Life Sciences Group (SLS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of SLS's total ratings.
What is SLS's price target?
SELLAS Life Sciences Group (SLS) average price target is $7 with a range of $6 to $8, implying a 488.24% from its last price of $1.19. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will SELLAS Life Sciences Group stock go up soon?
According to Wall Street analysts' prediction for SLS stock, the company can go up by 488.24% (from the last price of $1.19 to the average price target of $7), up by 572.27% based on the highest stock price target, and up by 404.20% based on the lowest stock price target.
Can SELLAS Life Sciences Group stock reach $2?
SLS's average twelve months analyst stock price target of $7 supports the claim that SELLAS Life Sciences Group can reach $2 in the near future.
What are SELLAS Life Sciences Group's analysts' financial forecasts?
SELLAS Life Sciences Group's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-24.013M (high $-22.89M, low $-25.136M), average SG&A $0 (high $0, low $0), and average EPS is $-0.417 (high $-0.397, low $-0.436). SLS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.934M (high $-25.934M, low $-25.934M), average SG&A $0 (high $0, low $0), and average EPS is $-0.45 (high $-0.45, low $-0.45).
Did the SLS's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2021), SELLAS Life Sciences Group's revenue was $5.7M, missing the average analysts' forecast of $7.22M by -21.05%. The company's EBITDA was $-2.403M, missing the average prediction of $-3.044M by -21.05%. SELLAS Life Sciences Group's net income was $-2.403M, missing the average estimation of $-3.044M by -21.05%. The company's SG&A was $3.56M, missing the average forecast of $4.51M by -21.05%. Lastly, the company's EPS was $-0.16, missing the average prediction of $-0.18 by -11.11%